Tony Mok, China...

Evandro de Azambuja, Brussels...

Gefitinib is a type of drug known as a tyrosine kinase inhibitor, and it targets cells with EGFR mutations. Most patients with EGFR mutation-positive non-small cell lung cancer respond to first-line EGFR tyrosine kinase inhibitors, but later acquire resistance. The primary objective of the trial was to show whether there was a difference in progression-free survival when gefitinib was continued in this situation. “This study was designed to ...

Women are indeed increasingly choosing oncology specialties in Greece, however, most decision-making posts are still dominated by men across the profession, in private practice, academia and national health environments. This needs to change, she said. The survey of 80 female members of the Hellenic Societies of Medical, Radiation and Surgical Oncology showed that while women were widely represented in workplaces, team leaders were men in 82% of ...

The results come from an online survey of 895 doctors from 12 countries in Europe, South America and Asia. All were practicing oncology specialists, with more than three years’ experience, treating more than fifteen patients a month. While 82% of those surveyed believed that deciding on a course of treatment is a process that should be shared between doctors and the patient, fewer than 23% of physicians believed their patients were always fully ...

Melanoma and colorectal cancer are the main field of progress
Johann de Bono
ESMO 2014
Scientific Chair...

A pertuzumab hozzáadása a trasztuzumab terápiához 56,5 hónapos teljes túlélést eredményez HER2-pozitív metasztatikus emlőkarcinómában. Ez az eddigi leghosszabb túlélés előrehaladott emlőrákban folytatott fázis III vizsgálatban. A CLEOPATRA vizsgálatban 808, korábban kezeletlen, HER2-pozitív, metasztatikus emlőrákban szenvedő betegen értékelték a pertuzumab, trasztuzumab és kemoterápia hatékonyságát és ...

Jean-Pascal Machiels, Belgium...

Thymidylate synthase is one of the proteins that is targeted by pemetrexed which is the most widely used chemotherapeutic regimen in the treatment of non-squamous NSCLC,” explains study author Professor Myung-Ju Ahn, from the Section of Hematology-Oncology at Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. “In this study, we tried to evaluate whether expression of thymidylate synthase is a predictive ...

At the ESMO 2014 Congress in Madrid, Dr Young-Chul Kim from Chonnam National University Medical School, South Korea, reported the results of an open-label phase III trial that included 149 patients with non-squamous non-small cell lung cancer (NSCLC) conducted at 14 centres in South Korea. “We wanted to conduct this study because pemetrexed plus platinum chemotherapy is the most commonly used regimen for treating patients with non-squamous...

The study included all residents aged between 50 and 74 years of age who had a first adenoma identified between January 1997 and December 2008. The researchers showed that 38.7% of these people had high-risk adenomas --meaning they were larger than 1 centimetre in diameter, involved the finger-like projections called villi in the intestinal lining, or exhibited a high grade of dysplasia....

Floriana Morgillo, ESMO Expert on Lung Cancer...

Az Amerikai Klinikai Onkológiai Társaság (ASCO) 2014-es, Chicagóban rendezett kongresszusán jelen volt az OLO.hu stábja, amelynek Dr. Jyoti Patel, a chicagói Northwestern University munkatársa, az ASCO tüdőrák-specialistája nyilatkozott a tüdőrák kezelésének, a kongresszus folyamán elhangzott újdonságairól. A professzor asszony kiemelte, hogy a tüdőrák kezelése a klinikai onkológia állandó fejlődésben levő ...

Interview with  Gregory Masters, ASCO Expert on Head&Neck Tumors, Lung Cancer, Medical Oncologist, Helen F. Graham Cancer Center & Research Institute, Newark...

Interview with  Jedd D. Wolchok, Chair of Congress Scientific Program Committee, Chief, Melanoma and Immunotherapeutics Service at Memorial Sloan Kettering Cancer Center, New York
...